Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-(3-tert-butyl‑1H‑pyrazol‑5‑yl)–N'–{4-chloro‑3–[(pyridin‑3-yloxy)methyl]phenyl}urea is a synthetic small molecule belonging to the n‑phenylureas class. It has a molecular formula of C20H22ClN5O2 and a molecular weight of approximately 399.9 g/mol[1][2]. The compound is listed as experimental and does not have any approved medical indications or known clinical development beyond preclinical or early research stages[2]. Its mechanism of action, biological targets, and therapeutic potential are not described in public databases, suggesting it may be an investigational chemical probe or screening hit rather than an advanced drug candidate.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-(3-tert-butyl-1H-pyrazol-5-yl)-N'-{4-chloro-3-[(pyridin-3-yloxy)methyl]phenyl}urea.